These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 28890196)

  • 1. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
    Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
    J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A; Roiz J; Briquet B; Greenberg DP
    Vaccine; 2015 Jan; 33(5):734-41. PubMed ID: 25444791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
    Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A; Roiz J; Aballea S
    PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
    Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
    Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluzone® High-Dose Influenza Vaccine.
    Robertson CA; DiazGranados CA; Decker MD; Chit A; Mercer M; Greenberg DP
    Expert Rev Vaccines; 2016 Dec; 15(12):1495-1505. PubMed ID: 27813430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Balasubramani GK; Choi WS; Nowalk MP; Zimmerman RK; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Murthy K; Jackson ML; Jackson LA; Chung JR; Spencer S; Fry AM; Patel M; Flannery B;
    Vaccine; 2020 Sep; 38(42):6562-6569. PubMed ID: 32800465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB
    Ann Pharmacother; 2021 Jan; 55(1):89-97. PubMed ID: 32578447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
    Gaglani M; Vasudevan A; Raiyani C; Murthy K; Chen W; Reis M; Belongia EA; McLean HQ; Jackson ML; Jackson LA; Zimmerman RK; Nowalk MP; Monto AS; Martin ET; Chung JR; Spencer S; Fry AM; Flannery B
    Clin Infect Dis; 2021 Apr; 72(7):1147-1157. PubMed ID: 32006430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
    DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
    N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.
    Manley HJ; Lacson EK; Aweh G; Chen Li N; Weiner DE; Miskulin DC; Hsu CM; Kapoian T; Hayney MS; Meyer KB; Johnson DS
    Am J Kidney Dis; 2022 Sep; 80(3):309-318. PubMed ID: 35288216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.
    Warmath CR; Ortega-Sanchez IR; Duca LM; Porter RM; Usher MG; Bresee JS; Lafond KE; Davis WW
    Value Health; 2023 May; 26(5):768-779. PubMed ID: 36436790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.